Indinavir: A pharmacologic and clinical review of a new HIV protease inhibitor

Connecticut Medicine

Volumn 60, Issue 12, 1996, Pages 723-727

  Lacy, Melinda K ^a,b   Abriola, Kenneth P ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; DIDANOSINE; FLUCONAZOLE; INDINAVIR; ISONIAZID; KETOCONAZOLE; LAMIVUDINE; MIDAZOLAM; PROTEINASE INHIBITOR; QUINIDINE; RIFAMPICIN; STAVUDINE; TERFENADINE; TRIAZOLAM; ZIDOVUDINE;

DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY;

ANTI-HIV AGENTS; CLINICAL TRIALS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR;

EID: 0030450738     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Crixivan package insert. West Point, Penn. Merck & Co., Inc., March 1995.
2. Drusano GL: Principles of therapy for HIV protease inhibitors. Abstracts of the Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 1995:371 [abstract S110].
3. Balani SK, Arisen BH, Mathai L, et al: Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995; 23:266-70.
4. Gulick R, Mellors J, Havlir D,et al: Potent and sustained antiretrovirat activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). Eleventh International Conference on AIDS. Vancouver, Canada. July 1996 [abstract Th.B.931].
5. Steigbigel RT, Berry P, Teppler H, et al: Extended follow-up of patients in a study of indinavir at 800 mg Q8H (2.4 G/D), 1000 mg Q8H (3.0 G/D) and 800 mg Q6H (3.2 G/D). Eleventh International Conference on AIDS. Vancouver. Canada, July 1996 [abstract Mo.B.412].
6. Massari F, Conant M, Mellors J, et al: A phase-II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV), and didanosine (DDI) vs indinavir alone and zidovudine/ didanosine in antiretroviral naive patients. Third Conference on Retroviruses and Opportunistic Infections. Washington, D.C., 1996 [abstract 200].
7. Massari F, Staszewski S, Berry P, et al: A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine-naive patients Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 1995 [abstract LB6].
8. Mellors J, Steigbigel R, Gulick R, et al: Antiretroviral activity of the oral protease inhibitor, MK-639, in p24 antigenemic HIV-1 infected patients with < 500 CD4/mm3. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 1995:235 [abstract 1172].
9. 3. Eleventh International Conference on AIDS. Vancouver, Canada, July 1996 [abstract LB.B.6017].
10. Stein DS, Fish DG. Chodakewitz J, et al: Follow-up data from an open label phase I evaluation of the HIV protease inhibitor MK-639. Third Conference on Retroviruses and Opportunistic Infections. Washington, D.C., 1996 [abstract 147].
11. Deutsch P, Teppler H, Squires K, et al: Antiviral activity of L-735,524, an HIV protease inhibitor, in infected patients. Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 1994:60 [abstract 159].
12. Falloon J, Owen C, Kovacs J, et al: MK-639 (Merck HIV protease inhibitor) with interleukin-2 (IL-2) in HIV. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 1995:236 [abstract 1176].
13. The indinavir (MK 639) pharmacokinetic study group. Indinavir (MK639) drug interaction studies. Eleventh International Conference on AIDS. Vancouver. Canada, July 1996 [abstract Mo.B.174].
14. Ho DD: Viral counts count in HIV infection. Science 1996; 272: 1124-25.
15. Mellors JW, Rinaldo Jr. CR, Gupta P, et al: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
16. Cameron DW, Heath-Chiozzi M, Kravcik S, et al: Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir. Update. Eleventh International Conference on AIDS. Vancouver, Canada, July 1996 [abstract Mo.B.411].
17. Lalezari J, Haubrich R, Burger HU, et al: Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase™ SQV) plus Hivid (zalcitabine, ddC) Eleventh International Conference on AIDS. Vancouver, Canada, July 1996. [abstract LB.B.6033].
18. Condra JH, Schleif WA, Blahy OM, et al: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-71.
19. Stefano V, Floridia M: HIV resistance to antiretroviral drugs. Improving the Management of HIV Disease 1996; 4:15-18.
20. Carpenter CCJ, Fischl MA, Hammer SM, et al: Antiretroviral therapy for HIV infection in 1996, recommendations of an international panel. JAMA 1996; 276:146-154.